GlycoMimetics (GLYC) Competitors $0.30 +0.01 (+2.55%) (As of 06:08 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GLYC vs. ANL, IKNA, CTMX, CLSD, OVID, PYRGF, BCAB, IMAB, MGX, and PDSBShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Adlai Nortye (ANL), Ikena Oncology (IKNA), CytomX Therapeutics (CTMX), Clearside Biomedical (CLSD), Ovid Therapeutics (OVID), PyroGenesis Canada (PYRGF), BioAtla (BCAB), I-Mab (IMAB), Metagenomi (MGX), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. Adlai Nortye Ikena Oncology CytomX Therapeutics Clearside Biomedical Ovid Therapeutics PyroGenesis Canada BioAtla I-Mab Metagenomi PDS Biotechnology Adlai Nortye (NASDAQ:ANL) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment. Do analysts recommend ANL or GLYC? Adlai Nortye presently has a consensus target price of $9.00, indicating a potential upside of 341.18%. GlycoMimetics has a consensus target price of $10.00, indicating a potential upside of 3,211.26%. Given GlycoMimetics' higher probable upside, analysts clearly believe GlycoMimetics is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00GlycoMimetics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings and valuation, ANL or GLYC? GlycoMimetics has lower revenue, but higher earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M15.06-$104.87MN/AN/AGlycoMimetics$10K1,947.30-$36.90MN/AN/A Which has more volatility and risk, ANL or GLYC? Adlai Nortye has a beta of -0.75, indicating that its stock price is 175% less volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Does the media favor ANL or GLYC? In the previous week, GlycoMimetics had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 1 mentions for GlycoMimetics and 0 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.00 equaled GlycoMimetics'average media sentiment score. Company Overall Sentiment Adlai Nortye Neutral GlycoMimetics Neutral Do insiders and institutionals hold more shares of ANL or GLYC? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ANL or GLYC more profitable? Adlai Nortye's return on equity of 0.00% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A GlycoMimetics N/A -160.93%-132.85% Does the MarketBeat Community believe in ANL or GLYC? GlycoMimetics received 307 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 59.55% of users gave GlycoMimetics an outperform vote. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesGlycoMimeticsOutperform Votes31559.55% Underperform Votes21440.45% SummaryGlycoMimetics beats Adlai Nortye on 8 of the 14 factors compared between the two stocks. Ad Brownstone ResearchVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up to a location just a few miles from here to show you Elon Musk’s next AI product. I promise what happens next will shock you…”Click here to see what happened Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.47M$6.61B$5.10B$9.18BDividend YieldN/A8.10%7.71%4.06%P/E RatioN/A5.2481.7813.97Price / Sales1,947.30376.441,438.94165.80Price / CashN/A22.4934.4335.60Price / Book0.505.464.824.98Net Income-$36.90M$149.55M$115.78M$223.34M7 Day Performance-8.32%0.96%3.59%1.38%1 Month Performance-26.77%-2.49%119.42%6.96%1 Year Performance-81.24%25.37%156.76%30.30% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics3.9332 of 5 stars$0.30+2.5%$10.00+3,211.3%-81.7%$19.47M$10,000.000.0050Analyst ForecastNews CoverageANLAdlai Nortye1.706 of 5 stars$2.25+0.9%$9.00+300.0%-81.3%$83.03M$5M0.00127Gap UpIKNAIkena Oncology3.3848 of 5 stars$1.72-0.6%$3.00+74.4%-11.6%$83.00M$659,000.00-1.4170CTMXCytomX Therapeutics4.0973 of 5 stars$1.06-0.5%$5.77+447.2%-19.7%$82.56M$101.21M6.24170Positive NewsGap DownCLSDClearside Biomedical2.2751 of 5 stars$1.08+2.9%$5.33+393.8%-5.5%$81.91M$8.23M-2.3330Positive NewsOVIDOvid Therapeutics4.3661 of 5 stars$1.15+0.4%$4.04+252.8%-65.7%$81.31M$390,000.00-2.4360Analyst RevisionGap DownPYRGFPyroGenesis CanadaN/A$0.44-4.9%N/A+38.0%$80.52M$9.14M-7.6790Gap DownBCABBioAtla2.1586 of 5 stars$1.67-0.9%$6.00+260.4%+3.1%$80.50M$11M-0.9960IMABI-Mab2.2162 of 5 stars$0.99+5.7%$8.00+711.5%-32.0%$80.34M$3.27M0.0034Positive NewsGap UpMGXMetagenomi2.0326 of 5 stars$2.14+3.4%$15.50+624.3%N/A$80.09M$55.08M0.00236Gap UpPDSBPDS Biotechnology1.6086 of 5 stars$2.14-2.3%$11.67+445.2%-57.9%$80.06MN/A-1.8920 Related Companies and Tools Related Companies Adlai Nortye Alternatives Ikena Oncology Alternatives CytomX Therapeutics Alternatives Clearside Biomedical Alternatives Ovid Therapeutics Alternatives PyroGenesis Canada Alternatives BioAtla Alternatives I-Mab Alternatives Metagenomi Alternatives PDS Biotechnology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLYC) was last updated on 12/9/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
